Wells Fargo & Company: Form 10-Q for the period ended Mar 31, 2025
Filed with the SEC on Apr 29, 2025 and accepted by EDGAR at Apr 29, 2025, 20:44 ET.
Management's discussion and analysis
As filed, 947 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following table shows Company repurchases of its common stock for each calendar month in the quarter ended March 31, 2025.
| Calendar month | Total number of shares repurchased (1) | Weighted average price paid per share | Approximate dollar value of shares that may yet be repurchased under the authorization (in millions) |
|---|---|---|---|
| January | — | $— | $7,274 |
| February | 36,567,268 | 79.13 | 4,380 |
| March | 7,971,867 | 76.05 | 3,774 |
| Total | 44,539,135 |
(1) All shares were repurchased under an authorization covering up to $30 billion of common stock approved by the Board of Directors and publicly announced by the Company on July 25, 2023. Unless modified or revoked by the Board of Directors, this authorization does not expire. In addition, on April 29, 2025, the Company publicly announced that the Board of Directors authorized the repurchase of up to an additional $40 billion of common stock.
Risk factors
As filed, 179 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Information in response to this item can be found under the “Financial Review – Risk Factors” section in this Report which information is incorporated by reference into this item.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-01-01 to 2025-03-31 | $20.15bn | us-gaap:RevenuesNetOfInterestExpense |
| Income tax | 3 months2025-01-01 to 2025-03-31 | $522.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-01-01 to 2025-03-31 | $4.89bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-01-01 to 2025-03-31 | $1.39 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-01-01 to 2025-03-31 | $1.41 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-01-01 to 2025-03-31 | 3,321,600,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2025-01-01 to 2025-03-31 | −$11.04bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Dividends paid | 3 months2025-01-01 to 2025-03-31 | $1.32bn | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 3 months2025-01-01 to 2025-03-31 | $3.50bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Total assets | At period end2025-03-31 | $1.95tn | us-gaap:Assets |
| Total liabilities | At period end2025-03-31 | $1.77tn | us-gaap:Liabilities |
| Long-term debt | At period end2025-03-31 | $173.66bn | us-gaap:LongTermDebt |
| Short-term borrowings | At period end2025-03-31 | $139.78bn | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2025-03-31 | $181.09bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000072971-25-000129. Last ingested by Listed: Nov 10, 2026, 21:52 ET. Listed shows no prices and gives no investment advice.